Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 30 | 2023 | 3177 | 3.330 |
Why?
|
Kidney Neoplasms | 28 | 2023 | 4274 | 2.830 |
Why?
|
Pelvis | 9 | 2020 | 736 | 1.630 |
Why?
|
Posture | 6 | 2020 | 952 | 1.070 |
Why?
|
Spine | 5 | 2020 | 1089 | 0.980 |
Why?
|
Gait | 4 | 2020 | 802 | 0.850 |
Why?
|
Neoplasms | 22 | 2023 | 21808 | 0.850 |
Why?
|
Cerebral Palsy | 4 | 2018 | 471 | 0.810 |
Why?
|
Immunotherapy | 11 | 2023 | 4601 | 0.740 |
Why?
|
Scoliosis | 4 | 2020 | 724 | 0.680 |
Why?
|
Imaging, Three-Dimensional | 9 | 2020 | 4032 | 0.670 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2022 | 798 | 0.640 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2020 | 11586 | 0.620 |
Why?
|
Salvage Therapy | 2 | 2018 | 1265 | 0.580 |
Why?
|
Nephritis, Interstitial | 1 | 2018 | 155 | 0.570 |
Why?
|
Kyphosis | 2 | 2020 | 236 | 0.560 |
Why?
|
Antineoplastic Agents | 8 | 2021 | 13553 | 0.560 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2022 | 2252 | 0.550 |
Why?
|
Down Syndrome | 3 | 2018 | 882 | 0.510 |
Why?
|
Walking | 4 | 2020 | 1173 | 0.510 |
Why?
|
Patient Positioning | 3 | 2018 | 325 | 0.490 |
Why?
|
Purines | 1 | 2018 | 600 | 0.480 |
Why?
|
Bone and Bones | 2 | 2020 | 2550 | 0.470 |
Why?
|
Aminopyridines | 1 | 2018 | 560 | 0.460 |
Why?
|
Physical Fitness | 1 | 2018 | 727 | 0.460 |
Why?
|
Benzimidazoles | 1 | 2018 | 854 | 0.420 |
Why?
|
Androgen Antagonists | 2 | 2021 | 1422 | 0.420 |
Why?
|
Cervical Vertebrae | 2 | 2018 | 968 | 0.400 |
Why?
|
Pandemics | 10 | 2022 | 8505 | 0.370 |
Why?
|
Lordosis | 2 | 2018 | 88 | 0.360 |
Why?
|
Pyridines | 3 | 2020 | 2861 | 0.360 |
Why?
|
Lymphatic Diseases | 1 | 2022 | 318 | 0.360 |
Why?
|
Therapies, Investigational | 1 | 2021 | 111 | 0.350 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 251 | 0.340 |
Why?
|
Humans | 93 | 2023 | 752341 | 0.340 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 304 | 0.340 |
Why?
|
Peritoneal Dialysis | 1 | 2020 | 146 | 0.330 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 100 | 0.320 |
Why?
|
Radiography | 6 | 2020 | 6964 | 0.320 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3066 | 0.310 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3185 | 0.310 |
Why?
|
Crohn Disease | 2 | 2019 | 2256 | 0.310 |
Why?
|
Spinal Curvatures | 1 | 2018 | 64 | 0.300 |
Why?
|
Early Detection of Cancer | 3 | 2021 | 3165 | 0.300 |
Why?
|
Femur | 2 | 2018 | 1288 | 0.300 |
Why?
|
Acetabulum | 2 | 2020 | 541 | 0.300 |
Why?
|
Immunologic Factors | 3 | 2021 | 1571 | 0.290 |
Why?
|
Piperazines | 1 | 2018 | 2486 | 0.290 |
Why?
|
Thigh | 1 | 2018 | 237 | 0.290 |
Why?
|
Interleukin-8 | 1 | 2020 | 701 | 0.280 |
Why?
|
Fixation, Ocular | 1 | 2018 | 234 | 0.280 |
Why?
|
Foot Deformities | 1 | 2016 | 34 | 0.280 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2019 | 851 | 0.270 |
Why?
|
Lebanon | 5 | 2019 | 241 | 0.270 |
Why?
|
Postural Balance | 1 | 2020 | 610 | 0.260 |
Why?
|
Spinal Cord Diseases | 1 | 2018 | 288 | 0.260 |
Why?
|
Pelvic Bones | 1 | 2017 | 271 | 0.260 |
Why?
|
Lower Extremity | 3 | 2020 | 1184 | 0.250 |
Why?
|
Healthcare Disparities | 3 | 2021 | 3302 | 0.250 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2023 | 3468 | 0.250 |
Why?
|
Algorithms | 2 | 2021 | 13900 | 0.240 |
Why?
|
Tomography, Spiral Computed | 1 | 2016 | 273 | 0.240 |
Why?
|
Joints | 1 | 2016 | 322 | 0.240 |
Why?
|
Immunoconjugates | 1 | 2022 | 865 | 0.240 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 2868 | 0.240 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2022 | 4495 | 0.240 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 3755 | 0.230 |
Why?
|
Body Mass Index | 3 | 2021 | 12796 | 0.230 |
Why?
|
Gait Disorders, Neurologic | 1 | 2016 | 233 | 0.230 |
Why?
|
Thoracic Vertebrae | 1 | 2018 | 594 | 0.230 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1572 | 0.220 |
Why?
|
Urban Population | 1 | 2022 | 2006 | 0.220 |
Why?
|
Male | 43 | 2023 | 354881 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2022 | 8422 | 0.220 |
Why?
|
Infection Control | 1 | 2020 | 971 | 0.210 |
Why?
|
Young Adult | 18 | 2020 | 57629 | 0.210 |
Why?
|
Retreatment | 2 | 2020 | 600 | 0.210 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2017 | 1201 | 0.210 |
Why?
|
Joint Diseases | 1 | 2016 | 457 | 0.200 |
Why?
|
Female | 40 | 2023 | 386053 | 0.200 |
Why?
|
Homosexuality, Male | 1 | 2019 | 1253 | 0.200 |
Why?
|
Upper Extremity | 1 | 2016 | 646 | 0.190 |
Why?
|
Rural Population | 1 | 2022 | 2239 | 0.190 |
Why?
|
Prostatic Neoplasms | 3 | 2021 | 11266 | 0.190 |
Why?
|
Tomography, X-Ray Computed | 7 | 2022 | 20348 | 0.190 |
Why?
|
Nephrectomy | 3 | 2022 | 1000 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9207 | 0.180 |
Why?
|
Anilides | 2 | 2020 | 407 | 0.180 |
Why?
|
Aged | 25 | 2023 | 166562 | 0.180 |
Why?
|
Retrospective Studies | 19 | 2023 | 79127 | 0.180 |
Why?
|
Survival Analysis | 4 | 2021 | 10177 | 0.180 |
Why?
|
Sexual Behavior | 1 | 2019 | 2061 | 0.170 |
Why?
|
Middle Aged | 25 | 2023 | 217019 | 0.170 |
Why?
|
Range of Motion, Articular | 1 | 2016 | 1572 | 0.170 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 7995 | 0.170 |
Why?
|
Protein Kinase Inhibitors | 4 | 2022 | 5594 | 0.170 |
Why?
|
Cross-Sectional Studies | 9 | 2020 | 25535 | 0.170 |
Why?
|
Functional Laterality | 1 | 2016 | 2256 | 0.170 |
Why?
|
Movement | 1 | 2016 | 1469 | 0.170 |
Why?
|
Adult | 24 | 2022 | 216913 | 0.170 |
Why?
|
Hip Joint | 1 | 2016 | 1001 | 0.170 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 205 | 0.160 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7576 | 0.160 |
Why?
|
Parenteral Nutrition, Total | 1 | 2019 | 304 | 0.160 |
Why?
|
Sarcoma | 1 | 2019 | 1788 | 0.160 |
Why?
|
Outpatients | 1 | 2016 | 1575 | 0.150 |
Why?
|
Antibodies, Monoclonal | 3 | 2022 | 9101 | 0.150 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2421 | 0.150 |
Why?
|
Adolescent | 14 | 2020 | 86765 | 0.150 |
Why?
|
Medical Oncology | 3 | 2022 | 2283 | 0.140 |
Why?
|
Enterobacteriaceae Infections | 1 | 2019 | 188 | 0.140 |
Why?
|
Cohort Studies | 7 | 2023 | 40984 | 0.140 |
Why?
|
Femur Neck | 1 | 2018 | 308 | 0.140 |
Why?
|
Aged, 80 and over | 13 | 2021 | 58300 | 0.140 |
Why?
|
Liver Failure | 1 | 2018 | 247 | 0.140 |
Why?
|
Biomedical Research | 1 | 2022 | 3379 | 0.130 |
Why?
|
Muscle, Skeletal | 2 | 2018 | 4877 | 0.130 |
Why?
|
DNA Methylation | 1 | 2020 | 4297 | 0.130 |
Why?
|
Combined Modality Therapy | 4 | 2020 | 8538 | 0.130 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 343 | 0.120 |
Why?
|
Carrier State | 1 | 2019 | 522 | 0.120 |
Why?
|
Multiple Organ Failure | 2 | 2023 | 386 | 0.120 |
Why?
|
Databases, Genetic | 1 | 2021 | 1745 | 0.120 |
Why?
|
Platelet Count | 1 | 2017 | 774 | 0.120 |
Why?
|
Melanoma | 1 | 2023 | 5620 | 0.120 |
Why?
|
Taxoids | 1 | 2017 | 664 | 0.120 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2020 | 300 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 552 | 0.120 |
Why?
|
Drug Utilization | 1 | 2020 | 1192 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2021 | 10198 | 0.120 |
Why?
|
Palliative Care | 2 | 2019 | 3573 | 0.110 |
Why?
|
Anthropometry | 1 | 2018 | 1342 | 0.110 |
Why?
|
Leukocyte Count | 1 | 2017 | 1590 | 0.110 |
Why?
|
Substance-Related Disorders | 1 | 2019 | 4319 | 0.110 |
Why?
|
Computer Simulation | 1 | 2016 | 6170 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2018 | 809 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2019 | 1546 | 0.100 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5279 | 0.100 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2019 | 626 | 0.100 |
Why?
|
Severity of Illness Index | 4 | 2022 | 15676 | 0.100 |
Why?
|
Methotrexate | 1 | 2019 | 1702 | 0.100 |
Why?
|
Oxygen Consumption | 1 | 2018 | 1838 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2018 | 2410 | 0.100 |
Why?
|
Tennessee | 1 | 2021 | 119 | 0.100 |
Why?
|
Pyrroles | 1 | 2018 | 1131 | 0.100 |
Why?
|
Health Facilities | 2 | 2022 | 571 | 0.100 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11064 | 0.100 |
Why?
|
Neutrophils | 2 | 2020 | 3724 | 0.100 |
Why?
|
Genomics | 4 | 2022 | 5727 | 0.100 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13165 | 0.100 |
Why?
|
Angiotensin I | 1 | 2021 | 55 | 0.090 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1060 | 0.090 |
Why?
|
Reproducibility of Results | 5 | 2020 | 19894 | 0.090 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 33 | 0.090 |
Why?
|
Censuses | 1 | 2022 | 200 | 0.090 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5207 | 0.090 |
Why?
|
Breast Neoplasms | 1 | 2018 | 20843 | 0.090 |
Why?
|
Risk Factors | 6 | 2022 | 73412 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2017 | 4861 | 0.090 |
Why?
|
Joint Instability | 2 | 2018 | 792 | 0.090 |
Why?
|
Cause of Death | 3 | 2022 | 3686 | 0.090 |
Why?
|
Respiratory Insufficiency | 1 | 2018 | 1209 | 0.090 |
Why?
|
Reference Values | 2 | 2017 | 4897 | 0.090 |
Why?
|
Indoles | 1 | 2018 | 1815 | 0.090 |
Why?
|
Cell Cycle | 1 | 2018 | 2928 | 0.080 |
Why?
|
Postoperative Period | 2 | 2019 | 1806 | 0.080 |
Why?
|
Cross Infection | 1 | 2019 | 1426 | 0.080 |
Why?
|
Lymphocytes | 1 | 2017 | 2592 | 0.080 |
Why?
|
Case-Control Studies | 3 | 2017 | 21841 | 0.080 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2021 | 358 | 0.080 |
Why?
|
Pyrimidines | 2 | 2018 | 2978 | 0.080 |
Why?
|
Telemedicine | 2 | 2020 | 2948 | 0.080 |
Why?
|
Gene Fusion | 1 | 2022 | 352 | 0.080 |
Why?
|
Mutation | 3 | 2021 | 29705 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6360 | 0.080 |
Why?
|
Drugs, Investigational | 1 | 2021 | 213 | 0.080 |
Why?
|
Survival Rate | 3 | 2020 | 12746 | 0.080 |
Why?
|
Ligases | 1 | 2020 | 331 | 0.080 |
Why?
|
Anatomy, Comparative | 1 | 2017 | 4 | 0.080 |
Why?
|
Calcaneus | 1 | 2020 | 141 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 556 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1822 | 0.080 |
Why?
|
Sulfonamides | 1 | 2018 | 1963 | 0.080 |
Why?
|
Angiotensin II | 1 | 2021 | 853 | 0.070 |
Why?
|
Condoms | 1 | 2019 | 310 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2441 | 0.070 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 248 | 0.070 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 738 | 0.070 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2021 | 453 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2023 | 2495 | 0.070 |
Why?
|
Brain Neoplasms | 1 | 2018 | 8892 | 0.070 |
Why?
|
Syphilis | 1 | 2019 | 236 | 0.070 |
Why?
|
Foot Joints | 1 | 2016 | 34 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2269 | 0.070 |
Why?
|
Treatment Outcome | 6 | 2020 | 64245 | 0.070 |
Why?
|
DNA-Binding Proteins | 3 | 2021 | 9551 | 0.070 |
Why?
|
Hydroxychloroquine | 2 | 2020 | 425 | 0.070 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 726 | 0.070 |
Why?
|
Foot | 1 | 2020 | 566 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2018 | 3560 | 0.060 |
Why?
|
Students, Medical | 1 | 2019 | 1884 | 0.060 |
Why?
|
Bone Density | 1 | 2018 | 3498 | 0.060 |
Why?
|
Genes, Tumor Suppressor | 1 | 2020 | 1056 | 0.060 |
Why?
|
Rotation | 1 | 2017 | 512 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6482 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1515 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12137 | 0.060 |
Why?
|
DNA Helicases | 1 | 2020 | 840 | 0.060 |
Why?
|
Receptors, Androgen | 1 | 2021 | 1068 | 0.060 |
Why?
|
Prospective Studies | 5 | 2022 | 53807 | 0.060 |
Why?
|
Biopsy | 2 | 2021 | 6743 | 0.060 |
Why?
|
Transcription Factors | 3 | 2021 | 12060 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3600 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12447 | 0.060 |
Why?
|
Organ Size | 1 | 2018 | 2247 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4271 | 0.050 |
Why?
|
HIV Infections | 1 | 2019 | 17006 | 0.050 |
Why?
|
Colonoscopy | 1 | 2021 | 1378 | 0.050 |
Why?
|
International Cooperation | 1 | 2019 | 1421 | 0.050 |
Why?
|
Accidental Falls | 1 | 2020 | 1040 | 0.050 |
Why?
|
Prognosis | 4 | 2020 | 29327 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 140 | 0.050 |
Why?
|
Child | 5 | 2018 | 78998 | 0.050 |
Why?
|
Electromyography | 1 | 2016 | 1373 | 0.050 |
Why?
|
Prostate-Specific Antigen | 1 | 2021 | 2524 | 0.050 |
Why?
|
Observer Variation | 1 | 2017 | 2579 | 0.050 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2597 | 0.050 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1873 | 0.040 |
Why?
|
Diet | 1 | 2018 | 7949 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 2 | 2021 | 2796 | 0.040 |
Why?
|
Georgia | 1 | 2020 | 186 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2019 | 3489 | 0.040 |
Why?
|
Mammography | 1 | 2021 | 2434 | 0.040 |
Why?
|
Databases, Factual | 2 | 2020 | 7898 | 0.040 |
Why?
|
Forecasting | 1 | 2019 | 2916 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2018 | 6234 | 0.040 |
Why?
|
Odds Ratio | 1 | 2022 | 9701 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2021 | 525 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 376 | 0.040 |
Why?
|
Middle East | 1 | 2019 | 222 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 198 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 632 | 0.040 |
Why?
|
Preceptorship | 1 | 2019 | 57 | 0.040 |
Why?
|
Diaphyses | 1 | 2018 | 64 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 267 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2022 | 3697 | 0.040 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2020 | 534 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2021 | 5070 | 0.040 |
Why?
|
Massachusetts | 1 | 2021 | 8707 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 584 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 694 | 0.040 |
Why?
|
Histone Demethylases | 1 | 2020 | 323 | 0.040 |
Why?
|
Indazoles | 1 | 2018 | 293 | 0.030 |
Why?
|
Femur Head | 1 | 2018 | 295 | 0.030 |
Why?
|
Macrophages | 1 | 2021 | 5693 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5163 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11007 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 887 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2020 | 1415 | 0.030 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2020 | 680 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2476 | 0.030 |
Why?
|
Registries | 1 | 2022 | 8362 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2020 | 1387 | 0.030 |
Why?
|
Mass Screening | 1 | 2021 | 5397 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 990 | 0.030 |
Why?
|
Quality Improvement | 1 | 2020 | 3797 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5786 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 2018 | 435 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2020 | 1237 | 0.030 |
Why?
|
Reference Standards | 1 | 2018 | 1004 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 1114 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1687 | 0.030 |
Why?
|
Heart Failure | 1 | 2018 | 11725 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2017 | 3325 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 843 | 0.030 |
Why?
|
Time Factors | 3 | 2020 | 39854 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1310 | 0.030 |
Why?
|
Universities | 1 | 2019 | 950 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2020 | 4631 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2021 | 1110 | 0.030 |
Why?
|
Prevalence | 1 | 2019 | 15506 | 0.030 |
Why?
|
Gene Deletion | 1 | 2020 | 2665 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 1987 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2064 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2020 | 2146 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2020 | 2036 | 0.020 |
Why?
|
Androgens | 1 | 2017 | 1285 | 0.020 |
Why?
|
Vaccination | 1 | 2021 | 3321 | 0.020 |
Why?
|
United States | 2 | 2022 | 71442 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39079 | 0.020 |
Why?
|
Animals | 2 | 2021 | 166802 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6501 | 0.020 |
Why?
|
Quality of Life | 1 | 2019 | 13153 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 4343 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3032 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2018 | 6781 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9236 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8420 | 0.020 |
Why?
|
Hemorrhage | 1 | 2018 | 3568 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10455 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2020 | 5369 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10475 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6846 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9355 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7747 | 0.020 |
Why?
|
Kidney | 1 | 2019 | 6983 | 0.010 |
Why?
|
Age Factors | 1 | 2020 | 18297 | 0.010 |
Why?
|
Risk Assessment | 1 | 2021 | 23783 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23233 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2018 | 11830 | 0.010 |
Why?
|